Login
News
18.11.2022 Desiree: dose escalation of everolimus published
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
Mehr ...10.11.2022 Deutscher Krebskongress
Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.
Mehr ...08.11.2022 GBG research at SABCS 2022
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
Mehr ...14.10.2022 Location of Subcutaneous Trastuzumab Injection
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
Mehr ...